8 minute read
Jun. 18, 2023
A P2X3-Selective Antagonist for Chronic Cough Without Taste Effects
camlipixant
oral BID P2X3 receptor antagonist Ph. III for first-line treatment of refractory chronic cough non-competitive homotrimeric receptor antagonist; discovery not disclosed GSK acquisition announcement, April 18, 2023 AstraZeneca Canada/NeoMed (adMare)/Bellus Health/GSK